Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial

[1]  A. Rezai,et al.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.

[2]  J. Jankovic,et al.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial , 2010, The Lancet Neurology.

[3]  D. Berg,et al.  Progression of Parkinson's disease in the clinical phase: potential markers , 2009, The Lancet Neurology.

[4]  H. Vinters,et al.  Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease , 2009, Neurology.

[5]  C. Goetz,et al.  The placebo treatments in neurosciences , 2008, Neurology.

[6]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[7]  S. Leurgans,et al.  Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions , 2008, Movement disorders : official journal of the Movement Disorder Society.

[8]  R. Watts,et al.  Spheramine for treatment of Parkinson’s disease , 2008, Neurotherapeutics.

[9]  S. Feldman,et al.  Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. , 2007, Journal of the American Academy of Dermatology.

[10]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[11]  P. Heiduschka,et al.  Tyrosinase biosynthesis and trafficking in adult human retinal pigment epithelial cells , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  K. Bartz-Schmidt,et al.  Tyrosinase biosynthesis in adult mammalian retinal pigment epithelial cells. , 2006, Experimental eye research.

[13]  Fabrizio Stocchi,et al.  Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications , 2006, The Lancet Neurology.

[14]  J. Jankovic.  An update on the treatment of Parkinson's disease. , 2006, The Mount Sinai journal of medicine, New York.

[15]  Mark Stacy,et al.  Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.

[16]  M. Cenci,et al.  Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective , 2005, Brain Research Bulletin.

[17]  R. Bakay,et al.  Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. , 2005, Archives of neurology.

[18]  D. Aarsland,et al.  Progression of motor impairment and disability in Parkinson disease , 2005, Neurology.

[19]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[20]  M. Hely,et al.  Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.

[21]  A. Björklund,et al.  Cell therapy in Parkinson’s disease , 2004, NeuroRX.

[22]  C. Honey,et al.  PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinson's disease , 2004, Experimental Neurology.

[23]  D. Russell,et al.  Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. , 2004, Archives of general psychiatry.

[24]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[25]  D. Casarini,et al.  l‐DOPA supply to the neuro retina activates dopaminergic communication at the early stages of embryonic development , 2003, Journal of neurochemistry.

[26]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[27]  D. Marchionini,et al.  Striatal Xenotransplantation of Human Retinal Pigment Epithelial Cells Attached to Microcarriers in Hemiparkinsonian Rats Ameliorates Behavioral Deficits without Provoking a Host Immune Response , 2002, Cell transplantation.

[28]  J. Jankovic,et al.  Functional decline in Parkinson disease. , 2001, Archives of neurology.

[29]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[30]  O. Isacson,et al.  Transplantation of embryonic porcine mesencephalic tissue in patients with PD , 2000, Neurology.

[31]  K. Marder,et al.  Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.

[32]  C. Olanow,et al.  Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. , 1999, Archives of neurology.

[33]  B. Cherksey,et al.  Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain , 1996, Neuroscience.

[34]  E. Mufson,et al.  Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies , 1996, The Journal of comparative neurology.

[35]  Scott T. Grafton,et al.  Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.

[36]  R. Bakay,et al.  Implantation of Spheramine in advanced Parkinson's disease (PD). , 2004, Frontiers in bioscience : a journal and virtual library.

[37]  R. Bakay,et al.  Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: a potential new cell therapy for Parkinson's disease. , 2003, Journal of neural transmission. Supplementum.

[38]  T. Subramanian.  Cell Transplantation for the Treatment of Parkinson's Disease , 2001, Seminars in neurology.

[39]  K. Follett.  The surgical treatment of Parkinson's disease. , 2000, Annual review of medicine.